OTS167 Inhibits FLT3 Expression in FLT3 Mutant Acute Myeloid Leukemia

被引：0
|
作者：
Eisfelder, Bartholomew [1 ]
Wynne, Joseph [1 ]
Colton, Margert [1 ]
Cheng, Jason [2 ]
Odenike, Olatoyosi [1 ]
Alachkar, Houda [3 ]
Stock, Wendy [1 ]
机构：
[1] Univ Chicago, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA
[2] Univ Chicago, Dept Pathol, Hematopathol Sect, 5841 S Maryland Ave, Chicago, IL 60637 USA
[3] Univ Southern Calif, Sch Pharm, Dept Clin Pharm & Pharmaceut Econ & Policy, Los Angeles, CA USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2019年 / 19卷
关键词：
FLT3; FLT3-ITD; MELK; OTS167; eIF4B; AML; acute myeloid leukemia;
D O I：
10.1016/j.clml.2019.07.133
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
AML-388
引用
收藏
页码：S239 / S240
页数：2
相关论文
共 50 条
  • [31] Gilteritinib Reduces FLT3 Expression in Acute Myeloid Leukemia Cells
    Thai, Thi Lam
    Han, Sun-Young
    BIOMOLECULES & THERAPEUTICS, 2024, 32 (05) : 577 - 581
  • [32] Integration of Hedgehog and mutant FLT3 signaling in myeloid leukemia
    Lim, Yiting
    Gondek, Lukasz
    Li, Li
    Wang, Qiuju
    Ma, Haley
    Chang, Emily
    Huso, David L.
    Foerster, Sarah
    Marchionni, Luigi
    McGovern, Karen
    Watkins, David Neil
    Peacock, Craig D.
    Levis, Mark
    Smith, Bruce Douglas
    Merchant, Akil A.
    Small, Donald
    Matsui, William
    SCIENCE TRANSLATIONAL MEDICINE, 2015, 7 (291)
  • [33] BETing on rational combination therapy in mutant FLT3 acute myeloid leukemia
    Stone, Richard M.
    HAEMATOLOGICA, 2021, 106 (04) : 931 - 932
  • [34] Optimizing FLT3 Inhibitor Use in Adult Acute Myeloid Leukemia with FLT3 Mutations Using Proteomics
    Magalhaes, Eduardo Sabino
    Hubner, Stefan
    Brown, Brandon D.
    Qiu, Yihua
    Kornblau, Steven M.
    BLOOD, 2023, 142
  • [35] Hematopoietic transplantation for acute myeloid leukemia with internal tandem duplication of FLT3 gene (FLT3/ITD)
    Brunet, Salut
    Martino, Rodrigo
    Sierra, Jorge
    CURRENT OPINION IN ONCOLOGY, 2013, 25 (02) : 195 - 204
  • [36] Expression of a recombinant FLT3 ligand and its emtansine conjugate as a therapeutic candidate against acute myeloid leukemia cells with FLT3 expression
    Zhang, Dengyang
    Guo, Yao
    Zhao, Yuming
    Yu, Liuting
    Chang, Zhiguang
    Pei, Hanzhong
    Huang, Junbin
    Chen, Chun
    Xue, Hongman
    Xu, Xiaojun
    Pan, Yihang
    Li, Ningning
    Zhu, Chengming
    Zhao, Zhizhuang Joe
    Yu, Jian
    Chen, Yun
    MICROBIAL CELL FACTORIES, 2021, 20 (01)
  • [37] Expression of a recombinant FLT3 ligand and its emtansine conjugate as a therapeutic candidate against acute myeloid leukemia cells with FLT3 expression
    Dengyang Zhang
    Yao Guo
    Yuming Zhao
    Liuting Yu
    Zhiguang Chang
    Hanzhong Pei
    Junbin Huang
    Chun Chen
    Hongman Xue
    Xiaojun Xu
    Yihang Pan
    Ningning Li
    Chengming Zhu
    Zhizhuang Joe Zhao
    Jian Yu
    Yun Chen
    Microbial Cell Factories, 20
  • [38] The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3/ITD acute myeloid leukemia cells
    E Chang
    S Ganguly
    T Rajkhowa
    C D Gocke
    M Levis
    H Konig
    Leukemia, 2016, 30 : 1025 - 1032
  • [39] The clinical development of FLT3 inhibitors in acute myeloid leukemia
    Knapper, Steven
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2011, 20 (10) : 1377 - 1395
  • [40] FLT3 ligand plasma levels in acute myeloid leukemia
    Peterlin, Pierre
    Gaschet, Joelle
    Guillaume, Thierry
    Garnier, Alice
    Eveillard, Marion
    Le Bourgeois, Amandine
    Cherel, Michel
    Debord, Camille
    Le Bris, Yannick
    Theisen, Olivier
    Mahe, Beatrice
    Dubruille, Viviane
    Godon, Catherine
    Robillard, Nelly
    Wuilleme, Soraya
    Touzeau, Cyrille
    Gastinne, Thomas
    Blin, Nicolas
    Lok, Anne
    Bonnet, Antoine
    Le Gouill, Steven
    Moreau, Philippe
    Bene, Marie-C
    Chevallier, Patrice
    HAEMATOLOGICA, 2019, 104 (06) : E240 - E243
12345